Choudhary S. Ahmed is an accomplished Molecular Biologist and Virologist with over five years of specialized experience spanning academic research, molecular diagnostics, and the biotechnology industry. Currently based in Mississauga, Ontario, his work focuses on the intersection of host-pathogen interactions, functional genomics, and antiviral drug discovery.
Dr. Ahmed earned his PhD in Molecular Biology and RNA Biology from the University of Nottingham, UK, where he conducted pivotal research into viral pathogenesis and translational regulation. Throughout his career, he has demonstrated a unique ability to bridge the gap between complex bench-side research and preclinical development. Notably, at ViroCarb, he spearheaded the construction of a lentivirus-based, whole-genome CRISPR screening platform from the ground up—optimizing three-plasmid systems to achieve high-titer viral production and establishing stable Cas9-expressing cell lines for high-throughput screening.
His technical repertoire is extensive, featuring advanced expertise in BSL-3 operations, flow-based assay development (FACS), and stable cell line engineering. During the SARS-CoV-2 pandemic, he was instrumental in developing infection readouts and established BSL-3 assays that allowed for scalable, controlled screening of host targets. His previous research at the University of Toronto (Cochrane Lab) further refined his expertise in HIV-1 RNA processing and the identification of host factors involved in vi
Choudhary S. Ahmed is an accomplished Molecular Biologist and Virologist with over five years of specialized experience spanning academic research, molecular diagnostics, and the biotechnology industry. Currently based in Mississauga, Ontario, his work focuses on the intersection of host-pathogen interactions, functional genomics, and antiviral drug discovery.
Dr. Ahmed earned his PhD in Molecular Biology and RNA Biology from the University of Nottingham, UK, where he conducted pivotal research into viral pathogenesis and translational regulation. Throughout his career, he has demonstrated a unique ability to bridge the gap between complex bench-side research and preclinical development. Notably, at ViroCarb, he spearheaded the construction of a lentivirus-based, whole-genome CRISPR screening platform from the ground up—optimizing three-plasmid systems to achieve high-titer viral production and establishing stable Cas9-expressing cell lines for high-throughput screening.
His technical repertoire is extensive, featuring advanced expertise in BSL-3 operations, flow-based assay development (FACS), and stable cell line engineering. During the SARS-CoV-2 pandemic, he was instrumental in developing infection readouts and established BSL-3 assays that allowed for scalable, controlled screening of host targets. His previous research at the University of Toronto (Cochrane Lab) further refined his expertise in HIV-1 RNA processing and the identification of host factors involved in vi